{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:00:42Z","timestamp":1781870442142,"version":"3.54.5"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Hangzhou Highlight Pharmaceutical Co., Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Psoriasis treatments that provide rapid and extensive itch relief as well as lesion clearance are currently inadequate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the efficacy and safety of the tyrosine kinase 2\/Janus kinase 1 inhibitor TLL-018 in patients with moderate-to-severe psoriasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This phase Ib, double-blind, placebo-controlled study (NCT05342428) randomized participants to receive TLL-018 10\u2005mg, 20\u2005mg, 30\u2005mg or placebo 2 : 2 : 2 : 1 orally twice daily for 12 weeks. The study included 73 patients with moderate-to-severe psoriasis. Eligible patients were aged 18\u201375\u2005years and were diagnosed with moderate-to-severe psoriasis at least 6\u2005months prior to screening, as defined by a Psoriasis Area and Severity Index (PASI) of \u2265 12, a body surface area \u2265 10% and a Physician\u2019s Global Assessment (PGA) of \u2265 3. The primary endpoint was safety of TLL-018. The efficacy endpoints were proportions of patients at week 12 achieving a \u2265 75% improvement from baseline in PASI (PASI 75), PGA of 0 or 1 (PGA 0\/1) and Dermatology Life Quality Index of 0 or 1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 73 participants were treated. TLL-018 was well tolerated, and most treatment-emergent adverse events were mild\/moderate. At week 12, 40% of patients (8 of 20) achieved PASI 75 with TLL-018 10\u2005mg, 48% (10 of 21) with 20\u2005mg, 62% (13 of 21) with 30\u2005mg and 9% (1 of 11) with placebo. The proportions of patients with PGA 0\/1 were 35%, 43%, 71% and 0%, respectively. Of the 21 patients in the TLL-018 30-mg group, 10 (48%) achieved a \u2265 90% improvement from baseline in PASI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>TLL-018 was well tolerated and showed promising efficacy at week 12 compared with placebo in patients with moderate-to-severe plaque psoriasis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf185","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T13:51:46Z","timestamp":1747230706000},"page":"670-677","source":"Crossref","is-referenced-by-count":5,"title":["Safety and efficacy of the selective tyrosine kinase 2\/Janus kinase 1 inhibitor TLL-018 in moderate-to-severe plaque psoriasis: a phase Ib, randomized, double-blind, placebo-controlled study"],"prefix":"10.1093","volume":"193","author":[{"given":"Jia-Qi","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hao","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Hospital of Jiaxing , Jiaxing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Wei","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Rheumatology, Dermatology Hospital of Southern Medical University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tie-Chi","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Renmin Hospital of Wuhan University , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ling","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Dermatology Hospital , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Zhen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second Affiliated Hospital of Harbin Medical University , Harbin ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congxin","family":"Liang","sequence":"additional","affiliation":[{"name":"Hangzhou Highlight Pharmaceutical Co., Ltd , Hangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3331-5538","authenticated-orcid":false,"given":"Xiao-Yong","family":"Man","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"2025091919452481300_ljaf185-B1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"2025091919452481300_ljaf185-B2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jaad.2019.08.011","article-title":"Psoriasis and mortality in the United States: data from the National Health and Nutrition Examination Survey","volume":"85","author":"Semenov","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025091919452481300_ljaf185-B3","doi-asserted-by":"crossref","first-page":"649408","DOI":"10.3389\/fmed.2021.649408","article-title":"Cutaneous and systemic psoriasis: classifications and classification for the distinction","volume":"8","author":"Yan","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025091919452481300_ljaf185-B4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.autrev.2018.11.007","article-title":"Amplifying the concept of psoriatic arthritis: the role of autoimmunity in systemic psoriatic disease","volume":"18","author":"Chimenti","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2025091919452481300_ljaf185-B5","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.2147\/CCID.S433367","article-title":"JAK inhibitors in psoriatic disease","volume":"16","author":"Megna","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2025091919452481300_ljaf185-B6","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1007\/s13555-023-01034-7","article-title":"Short-, mid-, and long-term efficacy of deucravacitinib versus biologics and nonbiologics for plaque psoriasis: a network meta-analysis","volume":"13","author":"Armstrong","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025091919452481300_ljaf185-B7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4049\/jimmunol.1003244","article-title":"Involvement of tyrosine kinase-2 in both the IL-12\/Th1 and IL-23\/Th17 axes in vivo","volume":"187","author":"Ishizaki","year":"01 2011","journal-title":"J Immunol"},{"key":"2025091919452481300_ljaf185-B8","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-difluorocyclopropyl)((1R,5 S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J Med Chem"},{"key":"2025091919452481300_ljaf185-B9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"2025091919452481300_ljaf185-B10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ibd\/izy364","article-title":"A JAK1 selective kinase inhibitor and tofacitinib affect macrophage activation and function","volume":"25","author":"De Vries","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2025091919452481300_ljaf185-B11","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"2025091919452481300_ljaf185-B12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13555-022-00878-9","article-title":"Novel therapies in plaque psoriasis: a review of tyrosine kinase 2 inhibitors","volume":"13","author":"Martin","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025091919452481300_ljaf185-B13","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, double-blind, placebo-controlled trial","volume":"140","author":"Forman","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2025091919452481300_ljaf185-B14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaad.2022.03.059","article-title":"Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study","volume":"87","author":"Tehlirian","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025091919452481300_ljaf185-B15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025091919452481300_ljaf185-B16","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1111\/jdv.18263","article-title":"The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis \u2013 a network meta-analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025091919452481300_ljaf185-B17","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/09546634.2020.1746734","article-title":"Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life","volume":"31","author":"Gerdes","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"2025091919452481300_ljaf185-B18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2025091919452481300_ljaf185-B19","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"2025091919452481300_ljaf185-B20","doi-asserted-by":"crossref","first-page":"e001838","DOI":"10.1136\/rmdopen-2021-001838","article-title":"Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study","volume":"7","author":"McInnes","year":"2021","journal-title":"RMD Open"},{"key":"2025091919452481300_ljaf185-B21","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.42519","article-title":"Efficacy and safety of the TYK2\/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl.","key":"2025091919452481300_ljaf185-B22","doi-asserted-by":"crossref","first-page":"AB306","DOI":"10.1016\/j.jaad.2024.07.1219","article-title":"52574 Safety and efficacy of selective TYK2\/JAK1 inhibitor, TLL-018, in moderate-to-severe plaque psoriasis","volume":"91","author":"Zheng","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025091919452481300_ljaf185-B23","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","article-title":"Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and Phase III clinical trial program","volume":"22","author":"Simpson","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2025091919452481300_ljaf185-B24","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/bjd\/ljae014","article-title":"Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials","volume":"190","author":"Lebwohl","year":"2024","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf185\/63181578\/ljaf185.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/4\/670\/63181578\/ljaf185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/4\/670\/63181578\/ljaf185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T23:45:29Z","timestamp":1758325529000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/4\/670\/8131573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,5,14]]},"published-print":{"date-parts":[[2025,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf185","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,5,14]]}}}